Sarepta Therapeutics' Elevidys for DMD shows revenue potential, with market cap justified at $11.4bn and potential for >50% ...

In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), with a price ...

We came across a bullish thesis on Sarepta Therapeutics, Inc. (SRPT) on Disruptive analytics’ Substack by Magnus Ofstad. In ...

Analysts at HC Wainwright raised their FY2024 earnings estimates for Sarepta Therapeutics in a note issued to investors on ...

Assenagon Asset Management S.A. trimmed its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 62.2% in the ...

Mizuho Securities analyst Uy Ear maintained a Hold rating on Revance Therapeutics (RVNC – Research Report) yesterday and set a price target of ...

SRPT insiders have traded $SRPT stock on the open market 6 times in the past 6 months. Of those trades, 3 have been purchases and 3 have been sales. Here’s a ...

The Speak Foundation will host the fourth International Limb Girdle Muscular Dystrophy (LGMD) Conference at the J.W. Marriott Orlando, Grande Lakes.

The FDA established its accelerated approval program in 1992 to allow drugs to reach the market quickly for life-threatening ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...